Wandercraft Financial Model
Health-tech Startup Financials (Free Excel Download)
Wandercraft builds self-balancing exoskeletons for the walking impaired, starting with a clinical rehab device (Atalante) and developing a personal exoskeleton for everyday use.
professionals from Deloitte
Used by professionals from
About this model
Wandercraft builds self-balancing exoskeletons for people with walking impairment, beginning with the Atalante clinical rehabilitation device. The company combines advanced hardware, software, and clinical use cases to help rehabilitation providers support mobility training for patients.
It is developing a personal exoskeleton that could extend the business from rehabilitation centres into everyday mobility. Commercial progress depends on device placements, regulatory milestones, clinical adoption, reimbursement or purchasing pathways, manufacturing scale, and service support for a complex physical product.
The model forecasts device placements, ASP, service contracts, rehabilitation utilisation, manufacturing cost, regulatory milestones, and personal-device adoption. It includes R&D, clinical support, warranty, inventory, sales cycles, gross margin, working capital, funding needs, and runway.
A turnkey financial model
Live formulas, no hardcoded values
Outputs are driven by live formulas, so the workbook updates from its assumptions instead of relying on hardcoded results.
All assumptions in one tab
Inputs are clearly marked in the Assumptions tab and separated from calculations, making it clear what to change and what to leave intact.
Statements always balancing
For integrated-statement models, the balance sheet, cash flow, and supporting schedules tie through properly.
Distinct schedules for clarity
Debt, working capital, taxes, and cash flow can get messy quickly. We group calculations in clear schedules, not across disconnected tabs.
No hidden macros or external links
There are no unexplained external workbook links or macros to undermine auditability or portability.
Changes flow through the model
Update a key driver and see the impact carry through the forecast, financing, and return outputs. We never use hardcoded numbers in formulas.
About Wandercraft
wandercraft.eu
How to build a detailed financial model for Wandercraft
A complete walkthrough of the business, drivers, and assumptions behind the downloadable Wandercraft model - distilled from its pitch deck and publicly available information.
Product & value proposition
- Product: Atalante - self-balancing (no crutches) powered exoskeleton for walking-impaired patients (SCI, stroke, MS, cerebral palsy, neuromuscular pathologies). Currently deployed in rehab hospitals.
- Pipeline: Personal Exo - slimmer design (60% less wide, 50% less deep vs Atalante), designed to fit in cars, regular seats and bathrooms; priced to compete with high-end power wheelchairs.
- Value prop: Only commercial company mastering dynamic-walk robotics for humans; addresses shortened life expectancy, pain, and social exclusion caused by wheelchair dependency.
Market
- Total market headline: €50bn.
- Patient funnel (source: Simon Kucher & Partners):
- Immediate opportunity (reimbursing countries, Atalante-compatible patients): 2m eligible patients
- Short term (broader country/patient set): 6m
- Medium term (SCI, stroke, MS, CP, neuromuscular - NA, Europe, China, Japan): 19m
- Long term (all wheelchair users worldwide): 30m
- ASP / pricing: Not explicitly stated; deck references "price of a high-end power wheelchair" as Personal Exo target price point. Atalante institutional pricing not disclosed.
Revenue model
- Channel: Direct sales to hospitals and rehab centres (B2B2P - hospital/insurer pays); future personal channel (B2C2P via reimbursement).
- Reimbursement: Countries with reimbursement are the immediate addressable pool; FDA submission for US access H1 2022.
- Revenue lines expected: Hardware sales (Atalante, Personal Exo), likely service/maintenance contracts - not confirmed in deck.
Traction & metrics
- 15 paying customers (hospitals/rehab centres)
- 50+ supportive KOLs in Europe and the US
- 3,000+ hours walked on Atalante
- 3+ million steps accumulated
- 10,000-motion user database for algorithm training
- 1 kHz real-time control execution
- CE-marked in less than a year; stroke MDR extension complete
Competition / moat
- Competitive landscape (bubble matrix): Wandercraft positioned top-right (highest technology threshold, largest market opportunity = Personal Mobility). Competing clusters: Walking Robots (Boston Dynamics), Surgical Robots (Intuitive, Auris), Military Exoskeletons (Lockheed Martin, Ekso, Sarcos), Industrial Exoskeletons (LG, Bosch, Ottobock, Sarcos), Medical Exoskeletons (Hocoma, ReWalk - Wandercraft also present here), Sport Exoskeletons (ROAM).
- Moat:
- 30 international patents, 100% IP ownership
- First commercial dynamic-walk algorithm implementation on exoskeletons
- Best motion generation framework claimed
- 10k-motion proprietary user database
- Research partnerships: Caltech, NJIT, University of Michigan, Shirley Ryan AbilityLab, MINES ParisTech
- ~85-person team (50 R&D PhDs/engineers, 15 clinical/regulatory/quality, 10 production, 10 customer success)
Team & funding ask / use of funds
- Co-founders:
- Matthieu Masselin - CEO (BCG, Ecole Polytechnique)
- Nicolas Simon - Chairman (BCG, Ecole Polytechnique)
- Jean-Louis Constanza - Development (former CEO Orange Vallée, Tele2 France; ENSAE/Dauphine/INSEAD)
- Key hires: Fabien Expert (Technology, ex-CNES, PhD); Vincent Philippon (Finance)
- Funding ask: €40m Series C contemplated (2021)
- Use of proceeds (proportions approximate from donut chart - no exact % given):
- R&D (largest slice)
- Clinic & RAQA (regulatory, assurance, quality - second slice)
- G&A (smallest slice)
- Existing investors: XAnge, idinvest, CEMAG, bpifrance, LBO France, Anaxago
- Advisor/bank: Bryan, Garnier & Co (placement agent)
Recommended financial model
- Archetype + why: MedTech hardware revenue model - unit-based P&L with a 3-statement build. This is a pre-revenue-scale, capital-intensive medical device company with two distinct product lines (Atalante clinical / Personal Exo consumer) and a reimbursement-gated sales cycle. A full 3-statement model with unit-volume driver tree is the right frame. Not a SaaS/ARR model; not an M&A/SPAC deck.
- Forecast horizon & granularity: 5 years (2022–2026), annual, with H1/H2 split for Year 1 to capture FDA clearance timing. Monthly optionally for cash runway given burn rate sensitivity.
- Key drivers & assumptions:
*Volume drivers*
- Atalante unit sales per year
- Personal Exo unit sales - begin 2024+
- FDA clearance year
- Countries with reimbursement coverage - gate for institutional sales
*Pricing*
- Atalante ASP
- Personal Exo target price
- Service/maintenance contract revenue
*Cost drivers*
- COGS / gross margin
- R&D spend - largest bucket from Series C proceeds; ASSUMED €15–20m of €40m raise goes to R&D over 3 years
- Clinic & RAQA spend; ASSUMED €12–15m for FDA submission, clinical trials, regulatory extensions
- G&A; ASSUMED €5–8m over raise period
- Headcount: ~85 employees as of 2021; ASSUMED ~120 by 2023 with Series C hiring
*Capital / runway*
- Series C €40m closes 2021; total prior capital ~€28m
- Cash runway: ASSUMED 3 years from close (to 2024) given R&D/regulatory spend intensity
- Scenarios (Base / Bull / Bear - which variables flex):
- Base: FDA cleared 2023; Atalante ramp ~30 units/yr by 2023; Personal Exo launch 2025; gross margin improves to 45% by 2025.
- Bull: FDA cleared H1 2023; reimbursement expands faster; Personal Exo at €25k ASP hits 500 units/yr by 2026 (consumer market opens).
- Bear: FDA delayed to 2024+; reimbursement stalls in key EU markets; Atalante capped at ~20 units/yr; Personal Exo delayed to 2027; Series D required by 2024.
- Required sheets / outputs:
- Assumptions - all drivers, toggleable by scenario
- Volume build - Atalante units, Personal Exo units, by country/channel
- Revenue build - hardware + service, by product line
- P&L - Revenue, COGS, Gross Profit, R&D, S&M, G&A, EBIT, EBITDA
- Cash & runway - operating cash burn, Series C drawdown, months of runway
- Balance sheet (simplified) - cash, capex, deferred revenue if any
- Dashboard - KPIs: units sold, ASP, gross margin %, cash runway, cumulative patients treated
Frequently asked
Is the Wandercraft financial model free?+
Yes. The Wandercraft model is a free Excel (.xlsx) download with live formulas. Sign up with your email and the workbook is yours to keep, review, and edit.
What's included in the model?+
A 5-year monthly forecast with P&L, cash flow and runway, valuation (exit multiple plus a DCF cross-check), MOIC/IRR returns, and unit economics, with live formulas throughout.
How was this model built?+
It was built from Wandercraft's pitch deck and publicly available information, then structured to investment-banking standards as a fully editable Excel model.
Can I change the assumptions?+
Yes. You can change assumptions and the live formulas will recalculate in the downloadable Excel model.
Have more financial modelling questions? Contact us
Created by ex-finance professionals
Hey, I’m Alex and I created Finamodel.
Over my years in the finance industry I kept building the same models over and over again. Same structure, same assumptions, different logo. So I started building frameworks to turn them into clean, reusable templates.
Every model here is one I’d actually use for a client, and I personally vet each one before it goes up.
I’m not an expert in every industry, but I’ve built enough models to know what belongs in one. And when something is completely foreign to me, I reach out to my network for experts to work on our models with us.
Having a template library on hand cuts a first build from hours to minutes.
Need help finding your model? You’ll find me in the Finamodel app!
Other Health-tech Startup Financial Models
Browse another startup in the same category.
98point6
B2B SaaS platform licensing an AI-powered virtual care technology stack to health systems, pivoted from running a direct-to-employer virtual clinic.
A-Champs
IoT-powered gamified training device (ROXs PRO) for sports/health professionals, evolving into a B2C smart coach app for families.
AccuRx
Patient-centred communication platform connecting everyone involved in a patient's care, starting with near-universal penetration in UK GP practices.
Aeris
Swiss-made premium air purifiers sold through DTC, retail, and dealer channels, with a recurring filter consumable attached to a connected mobile app.
Akido Labs
Akido Labs is a data-driven prevention platform that integrates siloed healthcare, municipal, and non-profit data to enable proactive outreach and case management for vulnerable populations (homeless, chronically ill, etc.).
Alloy
Telehealth + DTC subscription platform delivering menopause hormonal treatment (MHT) and holistic care to U.S. women 40+.
Astek Diagnostics
Point-of-care diagnostic device (Jiddu system) that confirms bacterial infections and antibiotic sensitivity in ~1 hour across four body fluid types (urine, CSF, effluent, blood).
Atom Limbs
Atom Limbs is building the first AI-powered, neural-controlled prosthetic arm sold direct-to-consumer on a subscription model.
